Barbara Buchberger

Dr. Barbara Buchberger

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
BBBarbara Buchberger
Barbara Buchberger
HHHendrik Huppertz
Hendrik Huppertz
LKLaura Krabbe
Laura Krabbe
BLBeate Lux
Beate Lux
JMJessica T. Mattivi
Jessica T. Mattivi
ASAris Siafarikas
Aris Siafarikas

27 March 2022 in Research Synthesis Methods
Verified
Journal Article
Open access
CSChristian Speckemeier
Christian Speckemeier
ANAnja Niemann
Anja Niemann
JWJürgen Wasem
Jürgen Wasem
BBBarbara Buchberger
Barbara Buchberger
SNSilke Neusser
Silke Neusser
The aim of the present work was to identify published methodological guidance for rapid reviews (RRs) and to analyze the recommendations with regard to time‐saving measures. A literature search was performed in PubMed and EMBASE in November 2020. In addition, a search based on Google Scholar and websites of governmental and non‐governmental organizations was conducted. Literature screening was carried out by two researchers independently. A total of 34 publications were included. These describe 38 distinct RR types. The timeframe to complete the identified RR types ranges from 24 h to 6 months (mean time 2.2 months). For most RR types a specific research question (n = 21) and a prioritizing search (n = 25; preference for e.g., systematic reviews and meta‐analyses) is employed. Different approaches such as reduced personnel in literature screening (n = 21) and data extraction (n = 21) are recommended. The majority of RR types include a bias assessment (n = 28) and suggest a narrative report focusing on safety and efficacy. The included RR types are heterogeneous in terms of completion time, considered domains and strategies to alter the standard systematic review methods. A rationale for the recommended shortcuts is rarely presented.

2 August 2011 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
BBBarbara Buchberger
Barbara Buchberger
MFM. Follmann
M. Follmann
DFD. Freyer
D. Freyer
HHH. Huppertz
H. Huppertz
AEA. Ehm
A. Ehm
JWJuergen Wasem
Juergen Wasem
Aims: Assessment of the safety, efficacy and effectiveness of growth factors alone or in combination with other technologies in the treatment of DFU including medical, economical, social, ethical and juridical aspects. Methods: We systematically searched relevant data bases limited to English and German language and publications since 1990. Review and assessment of the quality of publications followed methods conforming to widely accepted standards for evidence-based medicine and health economics. Results: We identified 25 studies comparing becaplermin, rhEGF, bFGF and the metabolically active skin grafts Dermagraft and Apligraf with standard wound care (SWC) alone or extracellular wound matrix. Study duration ranged from 12 to 20 weeks and the study population comprised between 17 and 382 patients. Treatment with becaplermin, rhEGF, Dermagraft and Apligraf resulted in a higher incidence of complete wound closure and shorter time to complete wound healing with statistically significant differences. Regarding the proportion of adverse events there was no difference between treatment groups. The methodological quality of the studies was affected by significant deficiencies. Economic evaluations showed becaplermin being cost-effective. Conclusions: Add-on therapy with growth factors and active skin substitutes for treating uncomplicated DFU could be an alternative to SWC alone. For explicit recommendations further studies with stronger evidence are necessary.

Verified
Closed access
BBBarbara Buchberger
Barbara Buchberger
KSKatharina Scholl
Katharina Scholl
LKLaura Krabbe
Laura Krabbe
LSLjuba Spiller
Ljuba Spiller
BLBeate Lux
Beate Lux

11 February 2018 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
BBBarbara Buchberger
Barbara Buchberger
LKLaura Krabbe
Laura Krabbe

8 November 2014 in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Verified
Journal Article
Open access
PDF file
BBBarbara Buchberger
Barbara Buchberger
EEE. von Elm
E. von Elm
GGG. Gartlehner
G. Gartlehner
HHH. Huppertz
H. Huppertz
GAG. Antes
G. Antes
JMJ.J. Meerpohl
J.J. Meerpohl
Praktisch tätige Ärzte treffen täglich eine Vielzahl von medizinischen Entscheidungen. Diese basieren überwiegend auf dem in der Ausbildung Erlernten und persönlicher Erfahrung, sollen heutzutage jedoch auch Patientenpräferenzen und die wissenschaftliche Evidenz für den Nutzen einer Intervention berücksichtigen. Mit dem Ziel der bestmöglichen Versorgung von Patienten bilden diese drei Aspekte gleichgewichtet die Grundlage für das Konzept der evidenzbasierten Medizin (EbM). Ohne Verständnis der methodischen Hintergründe ist die Gefahr von Fehleinschätzungen der Evidenz jedoch hoch und kann Behandlungsfehler zur Konsequenz haben. Im vorliegenden Beitrag werden das Konzept der systematischen Verzerrungen (Bias) und seine Bedeutung erläutert. Hierzu werden Ursachen, Auswirkungen und Methoden zur Minimierung von Bias dargestellt. Diese Inhalte sollen ein tieferes Verständnis vermitteln, um in der Praxis eine bessere Einschätzung von Studien und ihren Ergebnissen sowie die Umsetzung ihrer Empfehlungen zu erlauben. Das Risk-of-Bias (RoB)-Tool der Cochrane Collaboration ist ein Instrument zur Bewertung des Verzerrungspotentials in kontrollierten Studien. Zu seinen Stärken zählen eine einfache Anwendung, kurze Bearbeitungszeit, hohe Transparenz der Beurteilung und eine leicht verständliche graphische Darstellung der Ergebnisse. Mit dieser Publikation wird die deutsche Fassung des RoB-Tool veröffentlicht. Sie soll die Anwendung des Instruments auch außerhalb von Expertenkreisen erleichtern und über die Einschätzung der Validität von Studienergebnissen zur Entscheidungsfindung bei medizinischen Fragestellungen beitragen. Practicing physicians are faced with many medical decisions daily. These are mainly influenced by personal experience but should also consider patient preferences and the scientific evidence reflected by a constantly increasing number of medical publications and guidelines. With the objective of optimal medical treatment, the concept of evidence-based medicine is founded on these three aspects. It should be considered that there is a high risk of misinterpreting evidence, leading to medical errors and adverse effects without knowledge of the methodological background. This article explains the concept of systematic error (bias) and its importance. Causes and effects as well as methods to minimize bias are discussed. This information should impart a deeper understanding, leading to a better assessment of studies and implementation of its recommendations in daily medical practice. Developed by the Cochrane Collaboration, the risk of bias (RoB) tool is an assessment instrument for the potential of bias in controlled trials. Good handling, short processing time, high transparency of judgements and a graphical presentation of findings that is easily comprehensible are among its strengths. Attached to this article the German translation of the RoB tool is published. This should facilitate the applicability for non-experts and moreover, support evidence-based medical decision-making.